Peter L. Choyke

This study combines GD2-targeted photoimmunotherapy and 5-aminolevulinic acid photodynamic therapy to enhance cytotoxicity and reduce light-dose requirements in neuroblastoma and osteosarcoma.

This study shows that reducing GPC3 in liver cancer cells increases their sensitivity to radiation by extending G2/M arrest and activating the ATM/CHK2 pathway, with clinical evidence linking high GPC3 to worse outcomes in radiotherapy-treated HCC patients.

OncoBERT models somatic mutations in cancer to identify patient-specific subtypes and improve prediction of treatment response by integrating mutational context with clinical biomarkers.

This study investigates metabolic and imaging phenotypes in prostate cancer linked to RB1 and TP53 loss, finding metabolic changes that may inform multimodal imaging strategies.

A β-galactose-cleavable linker reduces kidney toxicity, enhances tumor targeting and therapeutic efficacy in radiopharmaceutical therapy.

HistoTME-v2 predicts cell type-specific transcriptomic signatures and spatial distributions from H&E images, outperforming baselines across 25 tumor types and multiple validation datasets.

The paper demonstrates a method to track ex vivo generated B cells in non-human primates using PET imaging, showing stable distribution and feasibility of repeated infusions.

This study identifies conserved TME subtypes in canine and human osteosarcomas that predict clinical outcomes independently of known biomarkers.